Literature DB >> 18628337

Muscle weakness correlates with muscle atrophy and precedes the development of inclusion body or rimmed vacuoles in the mouse model of DMRV/hIBM.

May Christine V Malicdan1, Satoru Noguchi, Yukiko K Hayashi, Ichizo Nishino.   

Abstract

Distal myopathy with rimmed vacuoles (DMRV), also called hereditary inclusion body myopathy (hIBM), is characterized clinically by weakness and atrophy that initially involves the distal muscles and pathologically by the presence of rimmed vacuoles (RVs) or intracellular protein deposits in myofibers. It is caused by mutations in the UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) gene that is important in sialic acid synthesis. Recently, we generated a mouse model (Gne(-/-)hGNED176VTg) that exhibits muscle weakness and pathological changes similar to DMRV patients. To gain better understanding of the pathomechanism of DMRV, we determined temporal changes in the overall motor performance of this model mouse for DMRV in correlation with the structure and function of isolated skeletal muscles and muscle pathology. These DMRV mice exhibited muscle weakness, decreased whole muscle mass and cross-sectional area (CSA), and reduced contractile power in an age-related manner. Single-fiber CSA further supported the finding of muscle atrophy that involved both type I and type II fibers. These results suggest that atrophy is highly correlated with reduced production of force at young age, both in vivo and ex vivo, thereby implicating the important role of atrophy in the pathomechanism of DMRV. In older age, and particularly in gastrocnemius muscles, RVs and intracellular inclusions were seen in type IIA fibers, further aggravating reduction of force and specific increase in twitch-tetanus ratio.

Entities:  

Mesh:

Year:  2008        PMID: 18628337     DOI: 10.1152/physiolgenomics.90219.2008

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  18 in total

Review 1.  Animal models of inflammatory myopathy.

Authors:  Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

2.  Sialic acid deficiency is associated with oxidative stress leading to muscle atrophy and weakness in GNE myopathy.

Authors:  Anna Cho; May Christine; V Malicdan; Miho Miyakawa; Ikuya Nonaka; Ichizo Nishino; Satoru Noguchi
Journal:  Hum Mol Genet       Date:  2017-08-15       Impact factor: 6.150

3.  Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice.

Authors:  Takahiro Yonekawa; May Christine V Malicdan; Anna Cho; Yukiko K Hayashi; Ikuya Nonaka; Toshiki Mine; Takeshi Yamamoto; Ichizo Nishino; Satoru Noguchi
Journal:  Brain       Date:  2014-07-24       Impact factor: 13.501

4.  A preclinical trial of sialic acid metabolites on distal myopathy with rimmed vacuoles/hereditary inclusion body myopathy, a sugar-deficient myopathy: a review.

Authors:  May Christine V Malicdan; Satoru Noguchi; Ichizo Nishino
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

5.  Peracetylated N-acetylmannosamine, a synthetic sugar molecule, efficiently rescues muscle phenotype and biochemical defects in mouse model of sialic acid-deficient myopathy.

Authors:  May Christine V Malicdan; Satoru Noguchi; Tomoharu Tokutomi; Yu-ichi Goto; Ikuya Nonaka; Yukiko K Hayashi; Ichizo Nishino
Journal:  J Biol Chem       Date:  2011-12-08       Impact factor: 5.157

6.  Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model.

Authors:  May Christine V Malicdan; Satoru Noguchi; Yukiko K Hayashi; Ikuya Nonaka; Ichizo Nishino
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

7.  Ganglioside GM3 levels are altered in a mouse model of HIBM: GM3 as a cellular marker of the disease.

Authors:  Thomas Paccalet; Zoé Coulombe; Jacques P Tremblay
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

Review 8.  GNE myopathy: current update and future therapy.

Authors:  Ichizo Nishino; Nuria Carrillo-Carrasco; Zohar Argov
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-07-07       Impact factor: 10.154

9.  Oral monosaccharide therapies to reverse renal and muscle hyposialylation in a mouse model of GNE myopathy.

Authors:  Terren K Niethamer; Tal Yardeni; Petcharat Leoyklang; Carla Ciccone; Adrian Astiz-Martinez; Katherine Jacobs; Heidi M Dorward; Patricia M Zerfas; William A Gahl; Marjan Huizing
Journal:  Mol Genet Metab       Date:  2012-10-18       Impact factor: 4.797

10.  Mice deficient in ribosomal protein S6 phosphorylation suffer from muscle weakness that reflects a growth defect and energy deficit.

Authors:  Igor Ruvinsky; Maximiliano Katz; Avigail Dreazen; Yuval Gielchinsky; Ann Saada; Nanette Freedman; Eyal Mishani; Gabriel Zimmerman; Judith Kasir; Oded Meyuhas
Journal:  PLoS One       Date:  2009-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.